IVVD

Invivyd, Inc.

Healthcare
Biotechnology
$231M market cap

Forecast run · Sep 14, 2026Upside rank 62 of 3,136

Model Signal

ForecastQ Daily Probabilities

78.5%

24.9%

55.4%

Analyst Consensus

Recommendation2.38/5 Buy

Last price$0.79

Price target$9.50

Implied move+1109.4%

Analysts8

ForecastQ Portfolios

IVVD is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.